Literature DB >> 8394795

Lomefloxacin clinical pharmacokinetics.

C D Freeman1, D P Nicolau, P P Belliveau, C H Nightingale.   

Abstract

Lomefloxacin is a quinolone antibiotic with chemical and microbiological properties similar to most commercially available agents of this class. There are differences, however, between lomefloxacin and other quinolones in activity against specific micro-organisms, a situation that is typical of most antibiotic classes. The pharmacokinetics of lomefloxacin support once- or twice-daily dosage, depending on the pathogen or site of infection. This is a result of its relatively high serum concentrations and long half-life. The outstanding pharmacokinetic features of lomefloxacin are its high degree of tissue distribution, lack of significant metabolism (and, therefore, no competitive drug interactions with other metabolised drugs showing a common metabolic pathway), and good oral absorption. Like most fluoroquinolones, lomefloxacin can chelate with heavy metals. However, this interaction can be eliminated by administering lomefloxacin 2h before the cation-containing products. Dosage adjustments are required in patients with renal dysfunction. However, patients with liver disease do not require alterations in lomefloxacin dosage regimens. The safety profile, lack of significant drug interactions and convenience of administration make lomefloxacin a useful agent in specific clinical settings.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394795     DOI: 10.2165/00003088-199325010-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  94 in total

1.  Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses.

Authors:  J Kavi; J Stone; J M Andrews; J P Ashby; R Wise
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

2.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

3.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

4.  Investigations into the mechanism of action of the antibacterial agent norfloxacin.

Authors:  G C Crumplin; M Kenwright; T Hirst
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

Review 5.  Usual and unusual antibacterial effects of quinolones.

Authors:  Y X Furet; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

6.  Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.

Authors:  J M Kovarik; A I Hoepelman; J M Smit; P A Sips; M Rozenberg-Arska; J H Glerum; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

7.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

8.  In-vitro activity of lomefloxacin in comparison with pefloxacin and ofloxacin.

Authors:  P Van der Auwera; P Grenier; Y Glupczynski; D Pierard
Journal:  J Antimicrob Chemother       Date:  1989-02       Impact factor: 5.790

9.  Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.

Authors:  D T Chu; P B Fernandes; A K Claiborne; E Pihuleac; C W Nordeen; R E Maleczka; A G Pernet
Journal:  J Med Chem       Date:  1985-11       Impact factor: 7.446

10.  Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.

Authors:  D C Hooper; J S Wolfson; K S Souza; E Y Ng; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

View more
  3 in total

1.  Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.

Authors:  L Rabbaa; S Dautrey; N Colas-Linhart; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 2.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 3.  Absorption interactions with fluoroquinolones. 1995 update.

Authors:  B M Lomaestro; G R Bailie
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.